Status Migrainosus in Pediatric Populations: A Systematic Evidence Synthesis

Efficacy of Symbravo® (MoSEIC(TM) meloxicam and rizatriptan) by Baseline Migraine-associated Disability: Post-hoc Analysis of the INTERCEPT Trial

Long-term Effects of Symbravo® (MoSEIC(TM) meloxicam and rizatriptan) on Headache Burden and Quality of Life: Results of the MOVEMENT Trial

Safety and Effectiveness of Rimegepant for Acute Treatment of Migraine in Adults Unsuitable for Triptan Use: Results from a 12-week Open-label Extension Phase.

Real-world Acute Treatment Optimization for Migraine with Ubrogepant: Results from the COURAGE II Study